Let’s start up with the current stock price of Recursion Pharmaceuticals Inc. (RXRX), which is $19.74 to be very precise. The Stock rose vividly during the last session to $20.40 after opening rate of $17.70 while the lowest price it went was recorded $17.70 before closing at $17.86.Recently in News on October 7, 2021, Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas. Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas. REC-2282 is a potentially first-in-class, orally bioavailable, CNS-penetrant small molecule HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas. You can read further details here
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Recursion Pharmaceuticals Inc. shares are logging -53.89% during the 52-week period from high price, and 15.17% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $17.14 and $42.81.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1148777 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Recursion Pharmaceuticals Inc. (RXRX) recorded performance in the market was -36.93%, having the revenues showcasing -39.24% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.56B, as it employees total of 218 workers.
Market experts do have their say about Recursion Pharmaceuticals Inc. (RXRX)
During the last month, 2 analysts gave the Recursion Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 28.37, with a change in the price was noted -5.51. In a similar fashion, Recursion Pharmaceuticals Inc. posted a movement of -21.82% for the period of last 100 days, recording 490,985 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RXRX is recording 0.02 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Technical breakdown of Recursion Pharmaceuticals Inc. (RXRX)
Raw Stochastic average of Recursion Pharmaceuticals Inc. in the period of last 50 days is set at 17.69%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 24.74%. In the last 20 days, the company’s Stochastic %K was 14.38% and its Stochastic %D was recorded 11.16%.
Bearing in mind the latest performance of Recursion Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -36.93%. The shares increased approximately by 6.76% in the 7-day charts and went up by -23.40% in the period of the last 30 days. Common stock shares were lifted by -39.24% during last recorded quarter.